Regen BioPharma, Inc. (OTCMKTS:RGBP – Get Free Report) was the recipient of a large increase in short interest during the month of September. As of September 30th, there was short interest totaling 297,566 shares, an increase of 708,390.5% from the September 15th total of 42 shares. Based on an average trading volume of 6,082,275 shares, the short-interest ratio is currently 0.0 days.
Regen BioPharma Price Performance
RGBP remained flat at $0.00 during midday trading on Friday. 1,244 shares of the company’s stock were exchanged, compared to its average volume of 16,360,283. Regen BioPharma has a one year low of $0.00 and a one year high of $0.03.
Regen BioPharma Company Profile
Regen BioPharma, Inc is a biotechnology company focused on developing regenerative medicine and immunotherapy technologies. Its research has included approaches intended to regulate stem-cell activity, restore damaged tissue, and modify immune responses associated with cancer and other diseases.
The company has publicly described several investigational programs, including HemaXellerate, a stem-cell-based approach studied for potential use in bone-marrow failure disorders; dCellVax, an experimental cancer-immunotherapy platform; and research involving NR2F6, an immune-regulatory target.
See Also
- Five stocks we like better than Regen BioPharma
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for Regen BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regen BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
